Abstract:AimTo assess the efficacy and safety of oral semaglutide, a novel glucagon‐like peptide 1 receptor agonist, for patients with type 2 diabetes mellitus. MethodsWe searched Medline, Embase, the Cochrane Library, and grey literature sources up to July 1st 2019 for randomized controlled trials (RCTs) comparing oral semaglutide with placebo or other antidiabetic agents. The primary outcome was change from baseline in glycated hemoglobin (HbA1c). Secondary outcomes included change from baseline in body weight and blood pressure, cardiovascular endpoints, severe hypoglycemia, gastrointestinal adverse events and diabetic retinopathy. We synthesized results using weighted mean differences (WMDs) for continuous outcomes, and odds ratios (ORs) for dichotomous outcomes, along with 95% confidence intervals (CIs). FindingsWe included 11 RCTs with 9890 patients in the systematic review. Compared with placebo, oral semaglutide reduced HbA1c and body weight (WMD –0.89%, 95% CI −1.07 to −0.71 and –2.99 kg, 95% CI −3.69 to −2.30 respectively). Oral semaglutide was also superior to other active comparators (including liraglutide, empagliflozin and sitaglipitin) in terms of HbA1c lowering (WMD –0.35%, 95% CI −0.43 to −0.26) and reduction of body weight (WMD –1.48 kg, 95% CI −2.28 to −0.67), and had a favorable effect on systolic blood pressure. Compared with placebo, oral semaglutide reduced all‐cause mortality (OR 0.58, 95% CI 0.37 to 0.92) and cardiovascular mortality (OR 0.55, 95% CI 0.31 to 0.98), and had a neutral effect on myocardial infarction, stroke, severe hypoglycemia and diabetic retinopathy. However, treatment with oral semaglutide increased the incidence of nausea, vomiting and diarrhea, while events of acute pancreatitis were rare. ConclusionsOral semaglutide can effectively and safely reduce blood glucose, body weight and systolic blood pressure. Nevertheless, it is associated with increased incidence of gastrointestinal adverse events. Further research is needed to clarify its long‐term safety and comparative effectiveness against other antidiabetic agents.This article is protected by copyright. All rights reserved.

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE

Semaglutide and obesity: beyond the nutritional and lifestyle intervention?

The Glucagon‐Like Peptide‐1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis

Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist

Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity

Wegovy (semaglutide): a new weight loss drug for chronic weight management

A review of oral semaglutide available evidence: A new era of management of diabetes with peptide in a pill form

Effect of Semaglutide in Individuals With Obesity or Overweight Without Diabetes

Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations

Semaglutide as a promising antiobesity drug

Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist

Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review

Anti-inflammatory benefits of semaglutide: State of the art

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide

GLP-1 Receptor Agonists - An Anaesthesiologist’s Perspective – A Comprehensive Review

Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Could GLP-1 Receptor Agonists like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?

Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach

Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice